Volume 1, Issue 1, Pages (June 2015)

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Middle age self-report risk score predicts cognitive functioning and dementia in 20– 40 years Eero Vuoksimaa, Juha O. Rinne, Noora Lindgren, Kauko Heikkilä,

DIAGNOSTIC ACCURACY AND CONFIDENCE IN THE CLINICAL DETECTION OF COGNITIVE IMPAIRMENT IN EARLY-STAGE PARKINSON’S DISEASE Kathryn A. Wyman-Chick, Phillip.

Volume 3, Issue 4, Pages (November 2017)

Volume 3, Issue 1, Pages (January 2017)

Volume 3, Issue 1, Pages 1-9 (January 2017)

Volume 3, Issue 3, Pages (September 2017)

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample Marie Eckerström,

Volume 1, Issue 1, Pages (June 2015)

Volume 3, Issue 2, Pages (June 2017)

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Volume 3, Issue 2, Pages (June 2017)

Alzheimer's disease drug development pipeline: 2017

Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis Sofia Lopes da Silva, Bruno Vellas, Saskia Elemans,

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

An amylin analog used as a challenge test for Alzheimer's disease

Volume 2, Issue 1, Pages (January 2016)

Volume 3, Issue 1, Pages (January 2017)

Chewing gum for the treatment of postoperative nausea and vomiting: a pilot randomized controlled trial J.N. Darvall, M Handscombe, K Leslie British.

Ben Sherwood, Andrew Xiao-Hua Zhou, Sandra Weintraub, Lan Wang

Courtney J. Warner, MD, MS, Spencer W. Greaves, MPH, Robin J

Early Dementia Distinguishing AD From MCI

Volume 49, Issue 5, Pages (May 2006)

Alzheimer's disease drug development pipeline: 2018

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

Fertility and Sterility Volume 103, Issue 6, Pages e37-e43 (June 2015)

Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study

Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial† A.J. Wikkelsø, H.M. Edwards, A. Afshari, J.

Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis Sofia Lopes da Silva, Bruno Vellas, Saskia Elemans,

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer’s Disease and Other Dementias Dement.

S. Imindu Liyanage, Clarissa Santos, Donald F. Weaver

Martin R. Farlow, MD Mayo Clinic Proceedings

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized,

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Effectiveness of glucosamine for symptoms of knee osteoarthritis: Results from an internet-based randomized double-blind controlled trial Timothy McAlindon,

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial Jill.

Inhaled aztreonam lysine vs

Community-acquired pneumonia: the evolving challenge

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized.

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized,

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

J. Ranstam Osteoarthritis and Cartilage

Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics:

Systematic review of antibiotic consumption in acute care hospitals

Lise L. Kjaergard, Sarah L. Frederiksen, Christian Gluud

Neuropsychological Assessment of Sport-Related Concussion

J.A Bolognese, M.Stat., T.J Schnitzer, M.D., Ph.D., E.W Ehrich, M.D.

Volume 4, Pages (October 2018)

Comparing two low-energy diets for the treatment of knee osteoarthritis symptoms in obese patients: a pragmatic randomized clinical trial B.F. Riecke,

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

Soma Brahmanandam, MD, MPH, Eric L. Ding, ScD, Michael S

A Smoking Cessation Intervention for Thoracic Surgery and Oncology Clinics: A Pilot Trial Elyse R. Park, PhD, MPH, Sandra Japuntich, PhD, Jennifer Temel,

Chewing gum for the treatment of postoperative nausea and vomiting: a pilot randomized controlled trial J.N. Darvall, M Handscombe, K Leslie British.

Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective Matthew Baumgart, Heather M. Snyder,

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Interreg-IPA Cross-border Cooperation Programme Romania-Serbia

A biomarker signal: Context-dependent hippocampal fMRI connectivity analysis of clinical trial measures in Alzheimer's disease Donald McLaren, Reisa.

Lana A. Tiersky, PhD, Vera Anselmi, PhD, Mark V

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics:

ONE-YEAR GLOBAL OUTCOME OF A COMPREHENSIVE, INDIVIDUALIZED, PERSON CENTERED MANAGEMENT (CI-PCM) PROGRAM + MEMANTINE IN ADVANCED AD: A RANDOMIZED CONTROLLED.

Volume 2, Issue 2, Pages (June 2016)

Efficacy and safety of oxymetazoline cream 1

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,

Susan D. Rountree, Alireza Atri, Oscar L. Lopez, Rachelle S. Doody

Presentation transcript:

Volume 1, Issue 1, Pages 23-36 (June 2015) Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease Gareth Maher-Edwards, Carolyn Watson, John Ascher, Carly Barnett, Diane Boswell, John Davies, Manuel Fernandez, Alexander Kurz, Orazio Zanetti, Beth Safirstein, Juan Paul Schronen, Marina Zvartau-Hind, Michael Gold Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, Pages 23-36 (June 2015) DOI: 10.1016/j.trci.2015.04.001 Copyright © 2015 GlaxoSmithKline Terms and Conditions

Fig. 1 Flow of subjects through Study 1 (A) and Study 2 (B). ITT, intent-to-treat. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2015 1, 23-36DOI: (10.1016/j.trci.2015.04.001) Copyright © 2015 GlaxoSmithKline Terms and Conditions

Fig. 2 Results from analysis of change from baseline using a MMRM model in the assessment of treatment effect of SB742457 on the ADAS-Cog (A, B), CIBIC+ (C), CDR-SB (D), ADCS-ADL (E, F), and RBANS (G, H) in the ITT population of Study 1 (panels A, C, E, G) and 2 (panels B, D, F, H). Data presented as adjusted mean ± 95% CI. Abbreviations: MMRM, mixed model for repeated measures; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CI, confidence interval; CIBIC+, Clinician Interview-Based Impression of Change Plus Caregiver Input; ADCS-ADL, Alzheimer's Disease Co-operative Study-Activities of Daily Living Scale; RBANS, Repeatable Battery for Assessment of Neuropsychological Status; ITT, intent-to-treat. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2015 1, 23-36DOI: (10.1016/j.trci.2015.04.001) Copyright © 2015 GlaxoSmithKline Terms and Conditions